University Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist.

The global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR). 

Swiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn.

Sodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells.

Dutch autoimmunity specialist Calypso Biotech BV has raised €20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and the company’s seed investor M Ventures.

Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.

Researchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants. 

It‘s only been nine years since the first blockchain technology applications in finance were introduced. Big players are now working to use distributed computing to protect pharma logistics from counterfeit drugs. Unlike current Internet-based solutions, the decentralised blockchain network is immune to manipulation or hacks, as transactions can be verified, recorded, and coordinated autonomously without third-party involvement.

Mundipharma today announced the appointment of Patrice Grand to the position of European Director of Corporate Communications.

Swiss newco Arvelle Therapeutics has baged a $180m (€159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (€88.4m) upfront from SK Biopharmaceuticals.